{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:05:50Z","timestamp":1787580350797,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ymthe.2022.04.019","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T05:53:30Z","timestamp":1651038810000},"page":"2709-2721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["RNAi-based modulation of IFN-\u03b3 signaling in skin"],"prefix":"10.1016","volume":"30","author":[{"given":"Qi","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas","family":"Echeverria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Chao","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Afshari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"MeHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenc","family":"Vangjeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Monopoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Biscans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Clauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-8071","authenticated-orcid":false,"given":"Anastasia","family":"Khvorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.04.019_bib1","first-page":"e71","article-title":"MIG in cutaneous systemic lupus erythematosus","volume":"170","author":"Ruffilli","year":"2019","journal-title":"Clin. Ter"},{"key":"10.1016\/j.ymthe.2022.04.019_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MOP.0000000000000375","article-title":"Understanding autoimmunity of vitiligo and alopecia areata","volume":"28","author":"Rork","year":"2016","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.ymthe.2022.04.019_bib3","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8+ T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2022.04.019_bib4","doi-asserted-by":"crossref","first-page":"eaav7561","DOI":"10.1126\/scitranslmed.aav7561","article-title":"IFN-\u03b3 enhances cell-mediated cytotoxicity against keratinocytes via JAK2\/STAT1 in lichen planus","volume":"11","author":"Shao","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2022.04.019_bib5","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2022.04.019_bib6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2022.04.019_bib7","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jid.2016.10.048","article-title":"CXCR3 depleting antibodies prevent and reverse vitiligo in mice","volume":"137","author":"Richmond","year":"2017","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2022.04.019_bib8","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T\u00a0cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2022.04.019_bib9","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.04.019_bib10","doi-asserted-by":"crossref","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2022.04.019_bib11","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of Baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.04.019_bib12","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.ymthe.2022.04.019_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.04.019_bib14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.04.019_bib15","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.04.019_bib16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.04.019_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.04.019_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2022.04.019_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2022.04.019_bib20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2022.04.019_bib21","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.04.019_bib22","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc\u2013siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2022.04.019_bib23","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/nar\/gky1239","article-title":"Diverse lipid conjugates for functional extra-hepatic siRNA delivery in\u00a0vivo","volume":"47","author":"Biscans","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2022.04.019_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jconrel.2019.03.028","article-title":"The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in\u00a0vivo","volume":"302","author":"Biscans","year":"2019","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2022.04.019_bib25","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.ymthe.2020.12.023","article-title":"Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles","volume":"29","author":"Biscans","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2022.04.019_bib26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nbt936","article-title":"Rational siRNA design for RNA interference","volume":"22","author":"Reynolds","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.04.019_bib27","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/nprot.2007.278","article-title":"A protocol for designing siRNAs with high functionality and specificity","volume":"2","author":"Birmingham","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2022.04.019_bib28","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1093\/nar\/gky745","article-title":"Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs","volume":"46","author":"Shmushkovich","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2022.04.019_bib29","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/nar\/gky037","article-title":"Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in\u00a0vivo","volume":"46","author":"Hassler","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2022.04.019_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/nar\/gkw1005","article-title":"Visualization of self-delivering hydrophobically modified siRNA cellular internalization","volume":"45","author":"Ly","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2022.04.019_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ymthe.2022.04.019_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nbt0112-3","article-title":"Incyte comes of age with JAK inhibitor approval","volume":"30","author":"Moran","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.04.019_bib33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1089\/nat.2018.0725","article-title":"Improving siRNA delivery in\u00a0vivo through lipid conjugation","volume":"28","author":"Osborn","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2022.04.019_bib34","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2022.04.019_bib35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug\u00a0delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2022.04.019_bib36","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1002\/eji.1830220933","article-title":"Distribution of interferon-gamma receptor in human tissues","volume":"22","author":"Valente","year":"1992","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2022.04.019_bib37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-\u03b3: implications for immune responses and autoimmune diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2022.04.019_bib38","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2022.04.019_bib39","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.4049\/jimmunol.1001049","article-title":"Inhibiting CXCR3-dependent CD8+ T\u00a0cell trafficking enhances tolerance induction in a mouse model of lung rejection","volume":"186","author":"Seung","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2022.04.019_bib40","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.immuni.2012.08.016","article-title":"CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation","volume":"37","author":"Groom","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2022.04.019_bib41","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1038\/ncomms8458","article-title":"Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints","volume":"6","author":"Mikucki","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.04.019_bib42","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/d41586-018-05867-7","article-title":"Gene-silencing technology gets first drug approval after 20-year wait","volume":"560","author":"Ledford","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.04.019_bib43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/pcmr.12559","article-title":"Differential expression of CXCL9, CXCL10, and IFN-\u03b3 in vitiligo and alopecia areata\u00a0patients","volume":"30","author":"Maouia","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ymthe.2022.04.019_bib44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.omtn.2020.06.006","article-title":"Cell type impacts accessibility of mRNA to silencing by RNA interference","volume":"21","author":"Ferguson","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2022.04.019_bib45","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41594-020-0495-4","article-title":"Ribosomes clear the way for siRNA targeting","volume":"27","author":"Ma\u0142ecka","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ymthe.2022.04.019_bib46","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1089\/jir.1997.17.583","article-title":"Infections in IFNGR-1-deficient children","volume":"17","author":"Jouanguy","year":"1997","journal-title":"J.\u00a0Interferon Cytokine Res."},{"key":"10.1016\/j.ymthe.2022.04.019_bib47","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/7701","article-title":"A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection","volume":"21","author":"Jouanguy","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2022.04.019_bib48","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/humu.23302","article-title":"IFN-\u03b3R1 defects: mutation update and description of the IFNGR1 variation database: van de VOSSE and van DISSEL","volume":"38","author":"van de Vosse","year":"2017","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2022.04.019_bib49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cytogfr.2011.01.001","article-title":"Regulation of hepatocyte fate by interferon-\u03b3","volume":"22","author":"Horras","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2022.04.019_bib50","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12985-021-01582-4","article-title":"CC and CXC chemokines play key roles in the development of polyomaviruses related pathological conditions","volume":"18","author":"Mohammadi","year":"2021","journal-title":"Virol. J."},{"key":"10.1016\/j.ymthe.2022.04.019_bib51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-chembioeng-060816-101514","article-title":"Engineering microneedle patches for vaccination and drug delivery to skin","volume":"8","author":"Prausnitz","year":"2017","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.ymthe.2022.04.019_bib52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41591-020-0787-6","article-title":"STAR particles for enhanced topical drug and vaccine delivery","volume":"26","author":"Tadros","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.04.019_bib53","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2020.04.038","article-title":"Topical delivery of siRNA into skin using ionic liquids","volume":"323","author":"Dharamdasani","year":"2020","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2022.04.019_bib54","doi-asserted-by":"crossref","first-page":"eabb6049","DOI":"10.1126\/sciadv.abb6049","article-title":"Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations","volume":"6","author":"Mandal","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2022.04.019_bib55","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/nbt.4297","article-title":"RNAi modulation of placental sFLT1 for the treatment of preeclampsia","volume":"36","author":"Turanov","year":"2018","journal-title":"Nat. Biotechnol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622002490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622002490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:02:51Z","timestamp":1718928171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001622002490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1525001622002490"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.04.019","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNAi-based modulation of IFN-\u03b3 signaling in skin","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}